Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Inventories — Work-in-process by Quarter
Inventories — Work-in-process ($M) ($M)
Pfizer Inventories — Work-in-process: $5,160M in Q2 2026, down 20.8% from a year earlier.
Latest, Q2 2026
5,160
Period ended Jun 28, 2026
Change on a year earlier
-20.8%
6,514 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
45
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Stage-of-completion breakdown of current inventories plus strategic long-cycle noncurrent inventories and supplier finance obligations.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Inventories — Work-in-process ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 5,160 | -20.8% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 5,713 | +2.9% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 5,634 | -7.7% | Form 10-Q (filed 2026-08-04) ↗ |
| Q3 2025 | Sep 28, 2025 | 6,038 | -16.9% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 6,514 | -7.9% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 5,553 | -11.5% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 6,101 | +7.3% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 29, 2024 | 7,267 | +11.5% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 7,072 | +10.3% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 6,273 | +2.3% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,688 | +3.1% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Oct 1, 2023 | 6,515 | +43.5% | Form 10-Q (filed 2023-11-08) ↗ |
| Q2 2023 | Jul 2, 2023 | 6,409 | +23.4% | Form 10-Q (filed 2023-08-09) ↗ |
| Q1 2023 | Apr 2, 2023 | 6,129 | +26.6% | Form 10-Q (filed 2023-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 5,519 | +24.8% | Form 10-K (filed 2024-02-22) ↗ |
| Q3 2022 | Oct 2, 2022 | 4,540 | +1.6% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jul 3, 2022 | 5,194 | +18.4% | Form 10-Q (filed 2022-08-10) ↗ |
| Q1 2022 | Apr 3, 2022 | 4,843 | +11.0% | Form 10-Q (filed 2022-05-11) ↗ |
| Q4 2021 | Dec 31, 2021 | 4,424 | -0.3% | Form 10-K (filed 2023-02-23) ↗ |
| Q3 2021 | Oct 3, 2021 | 4,469 | -10.9% | Form 10-Q (filed 2021-11-12) ↗ |
| Q2 2021 | Jul 4, 2021 | 4,388 | -8.8% | Form 10-Q (filed 2021-08-12) ↗ |
| Q1 2021 | Apr 4, 2021 | 4,364 | -12.1% | Form 10-Q (filed 2021-05-13) ↗ |
| Q4 2020 | Dec 31, 2020 | 4,436 | +7.4% | Form 10-K (filed 2022-02-24) ↗ |
| Q3 2020 | Sep 27, 2020 | 5,014 | +3.0% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 28, 2020 | 4,810 | -8.4% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 29, 2020 | 4,962 | -4.2% | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 4,131 | -12.1% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 29, 2019 | 4,866 | +2.1% | Form 10-Q (filed 2019-11-07) ↗ |
| Q2 2019 | Jun 30, 2019 | 5,249 | +15.6% | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 5,182 | +15.5% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 4,701 | +20.3% | Form 10-K (filed 2020-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 4,764 | +17.1% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jul 1, 2018 | 4,542 | +17.7% | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Apr 1, 2018 | 4,485 | +30.2% | Form 10-Q (filed 2018-05-10) ↗ |
| Q4 2017 | Dec 31, 2017 | 3,908 | +5.7% | Form 10-K (filed 2019-02-28) ↗ |
| Q3 2017 | Oct 1, 2017 | 4,070 | +2.6% | SEC Filing ↗ |
| Q2 2017 | Jul 2, 2017 | 3,860 | -1.8% | SEC Filing ↗ |
| Q1 2017 | Apr 2, 2017 | 3,445 | -12.9% | SEC Filing ↗ |
| Q4 2016 | Dec 31, 2016 | 3,696 | -6.0% | Form 10-K (filed 2018-02-22) ↗ |
| Q3 2016 | Oct 2, 2016 | 3,965 | -5.6% | SEC Filing ↗ |
| Q2 2016 | Jul 3, 2016 | 3,931 | +13.7% | SEC Filing ↗ |
| Q1 2016 | Apr 3, 2016 | 3,957 | +15.9% | SEC Filing ↗ |
| Q4 2015 | Dec 31, 2015 | 3,932 | – | Form 10-K (filed 2017-02-23) ↗ |
| Q3 2015 | Sep 27, 2015 | 4,198 | – | SEC Filing ↗ |
| Q2 2015 | Jun 28, 2015 | 3,458 | – | SEC Filing ↗ |
| Q1 2015 | Mar 29, 2015 | 3,414 | – | SEC Filing ↗ |
Breakdown
What makes up inventories — Work-in-process
- Inventories — Finished goods ($M)3,887 · Q2 2026
- Inventories — Raw materials & supplies ($M)898 · Q2 2026
- Noncurrent inventories (included in Other noncurrent assets) ($M)2,419 · Q2 2026
- Supplier Finance Program — Confirmed obligations outstanding ($M)545 · Q2 2026
- Supplier Finance Program — Obligations added during year ($M)–
- Supplier Finance Program — Obligations settled during year ($M)–
Cite this data
StockData. (2026). Pfizer Inventories — Work-in-process ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/inv-wip
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.